The Effect of Pravastatin on Hypoxia Inducible Factor-1-Alpha (HIF-1-A) Expression on the Placenta of Preeclampsia Wistar Rats
DOI:
https://doi.org/10.37275/bsm.v6i14.658Keywords:
HIF-1-A, In vivo, Pravastatin, Preeclampsia, PregnancyAbstract
Background: Preeclampsia (PE) is hypertension in pregnancy that currently occurs starting from the time of placentation and is 1 of the five leading causes of maternal death. The main cause of preeclampsia is the placenta, which is hypoxic, and the spiral artery remodeling fails. Hypoxia-inducible factor-1-alpha (HIF-1-A), a marker in the nucleus, is overexpressed during tissue hypoxia. Pravastatin has a pleiotropic effect as the synthesis of nitric oxide (NO), a strong vasodilator to correct hypoxia. This study aims to explore the potential of pravastatin against functional abnormalities or placental hypoxia through in vivo HIF-1-A expression.
Methods: This study is an experimental study using female Wistar rats (Rattus norvegicus) induced by preeclampsia. Assessment of HIF-1-A expression was carried out by immunohistochemistry. Data analysis was performed using SPSS, and then univariate and bivariate tests were performed.
Results: Administration of pravastatin at a dose of 10 mg/kg BW showed the most optimal potential in reducing the expression of HIF-1-A protein, indicating tissue hypoxia. Pravastatin doses of 2.5 mg/kg BW and 5 mg/kg BW also could reduce HIF-1-A protein expression better than the K+ group who were not given pravastatin.
Conclusion: Pravastatin can reduce the expression of HIF-1-A protein in pre-eclamptic rats, which indicates the potential of pravastatin to reduce the incidence of preeclampsia.
Authors
- Predixon Leonardo Napitupulu1*
- Herman Kristanto1
- Putri Sekar Wiyati1
- Yuli Trisetyono1
- Besari Adi Pramono1
- 1Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Diponegoro/Dr. Kariadi General Hospital, Semarang, Indonesia
Corresponding author Predixon Leonardo Napitupulu — drleonardonapitupulu@students.undip.ac.id
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
